B+
Bull case
25%
Probability
Target price
$1,080.00
Analysis reference price unavailable
Analysis 2026-06-20 · RankAlpha Sentiment Codex
ARGX
argenx SECNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Primary company releases support a still-strong operating story: Q1 2026 product net sales reached $1.298 billion, up 63% year over year, and the May 2026 gMG label expansion plus positive ocular MG data extend the franchise runway [#IR-2026-05-07] [#PR-2026-05-08] [#PR-2026-02-26].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.3.
What can break
ALKIVIA, EMPASSION, and other pipeline readouts still carry binary clinical risk; supportive extension data do not remove registrational uncertainty.
Momentum
81
Value
60
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $920.00 · Bull $1,080.00 · Bear $720.00Analysis 2026-06-20; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $1,198.28
Why
Momentum81 · Δ7d +15.7
Value60 · Δ7d -0.0
Sentiment53 · Δ7d +3.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +3.3.
Contradictions & invalidation
- • ALKIVIA, EMPASSION, and other pipeline readouts still carry binary clinical risk; supportive extension data do not remove registrational uncertainty.
- • Direct FcRn competition from Immunovant, UCB, and Johnson & Johnson could pressure long-term share, pricing, or durability assumptions if rival labels and dosing profiles compare favorably.
- • The evidence packet still looks like a monitoring setup, not a fresh inflection thesis: deterministic evidence quality is low, analyst target count is unavailable, direct FcRn competition is active in gMG, and the next major rerating likely needs clean myositis or later pipeline data rather than another read-through from already-strong VYVGART demand.
Catalyst clock
2026-08-15
All-serotype gMG label expansion now needs to convert into faster U.S. uptake
Lead driver: Sentiment · See AI snapshot
Momentum
81
9% active weight
Current posture
7d trendImproving
Δ7d
+15.7
Δ21d
+16.3
Value
60
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+1.0
Sentiment
53
62% active weight
Current posture
7d trendImproving
Δ7d
+3.3
Δ21d
+6.3
Why this grade
Composite grade C. Momentum 80.6 / Value 60.0 / Sentiment 53.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-20. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$920.00
Analysis reference price unavailable
Analysis 2026-06-20 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$720.00
Analysis reference price unavailable
Analysis 2026-06-20 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$61.95B
Beta
0.72
Shares Out
62.56M
P/E (TTM)
34.6
P/S (TTM)
13.68
P/FCF (TTM) · Derived
55.73
Rev YoY
+96.6%
EPS YoY
+272.7%
Gross Margin
+89.5%
Op Margin
+28.8%
Net Debt
-$4.39B
Current Ratio
5.12
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data